First Tracks Biotherapeutics (TRAX) — Working Capital to Net Assets Ratio
First Tracks Biotherapeutics (TRAX) has a Working Capital to Net Assets ratio of 90.3% as of December 2024. Working capital of $353.75 Million (current assets of $389.93 Million minus current liabilities of $36.18 Million) is measured against net assets of $391.60 Million. A higher ratio indicates strong short-term liquidity financed by the equity base. See TRAX equity to assets ratio to measure how much of total assets are equity-financed.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
First Tracks Biotherapeutics Working Capital to Net Assets (2023–2024)
This chart shows how First Tracks Biotherapeutics's Working Capital to Net Assets ratio has evolved across 2 annual periods from 2023 to 2024. As of December 2024, the ratio stands at 90.3%, reflecting working capital of $353.75 Million against net assets of $391.60 Million USD. Check TRAX goodwill-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
Annual Working Capital to Net Assets for First Tracks Biotherapeutics (2023–2024)
The table below presents the year-by-year Working Capital to Net Assets ratio for First Tracks Biotherapeutics from 2023 to 2024, covering 2 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For live market cap and the full company profile, see First Tracks Biotherapeutics market cap and net worth.
| Year | WC/NA Ratio | Working Capital (USD) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2024 | 90.3% | $353.75 Million | $391.60 Million | $389.93 Million | $36.18 Million | ▼ -2.5 pp |
| 2023 | 92.8% | $380.33 Million | $409.85 Million | $398.56 Million | $18.22 Million | — |